Growth in use of statins after trials is not targeted to most appropriate patients

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 4, 2000, Pages 438-441

  Feely, John ^a   McGettigan, Patricia ^b   Kelly, Alan ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; SIMVASTATIN; STATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DRUG USE; DRUG UTILIZATION; FEMALE; HEALTH SERVICE; HUMAN; IRELAND; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 0034112856     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.105152     Document Type: Article

References (19)

1. 1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. 2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
3. 3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
4. 4. NHS Executive Standing Medical Advisory Committee Statement on use of statins. London: Department of Health; 1997.
5. 5. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996;348:387-8.
6. 6. Baxter C, Hones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practise. BMJ 1998;317:1134-5.
7. 7. Feely J. The influence of Pharmacoeconomic factors on prescribing patterns in Ireland. Pharmacoeconomics 1992;2:99-106.
8. 8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
9. 9. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
10. 10. Fairhurst K, Huby G. From trial data to practical knowledge: a qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. BMJ 1998;317:1130-4.
11. 11. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995;310:975-8.
12. 12. Rosengren A. Cholesterol: how low is low enough? BMJ 1998;317:425-6.
13. 13. Hobbs FDR. Putting evidence into practice. Eur Heart J 1999:20(suppl Q):11-3.
14. 14. Walley T, Haycox A, Barton S. Drug Rationing in the UK National Health Service: current status and future prospects. Pharmacoeconomics 1997:12:870-4.
15. 15. Feely J, Chan R, McManus J, O'Shea B. The influence of Hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 1999:16:175-81.
16. 16. O'Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, Marciniak TA, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA 1999;281:627-33.
17. 17. Frolkis JP, Zyanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998;98:851-5.
18. 18. EUROASPIRE Study Group. A European Society of Cardiology survey on secondary prevention of coronary heart disease: principal results. Eur Heart J 1997;18:1569-82.
19. 19. Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19:1434-503.